Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. It has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Adaptive Biotechnologies Corporation

In a report released today, William Bonello from Craig-Hallum maintained a Buy rating on Adaptive Biotechnologies, with a price target of $18.00. B...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ADPT	$18.61	+14.03%	5.07M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ADPT	$18.61	+14.0%	5.07M
3
4
5
6

ADPT

ADPT

Get Adaptive Biotechnologies Corporation Data in Excel

Get Adaptive Biotechnologies Corporation Data in Excel